KDAc Therapeutics is a biotechnology company anchored in technologies licensed from the Broad Institute of MIT and Harvard that are designed to translate discoveries in lysine acetylation and epigenetic regulation into novel treatments for cancer patients. In Summer 2019, OnKure, Inc. - discovery and development of selective histone deacetylase inhibitors - entered into an exclusive license and option agreement with KDAc Therapeutics, Inc. to support continued development of KDAcs selective histone deacetylase 3 (HDAC3) inhibitor program. The collaboration focuses on continued advancement of KDAcs lead candidate, KDAc-0001 (or OKI-422) --- Histone deacetylase (HDAC) inhibitors in a class of anti-cancer agents that play important roles in epigenetic and non-histone protein regulation, including death, apoptosis, and cell cycle arrest in cancer cells.
